ABSTRACT
ABSTRACT Objective Investigate the therapeutic response of acromegaly patients to pegvisomant (PEGV) in a real-life, Brazilian multicenter study. Subjects and methods Characteristics of acromegaly patients treated with PEGV were reviewed at diagnosis, just before and during treatment. All patients with at least two IGF-I measurements on PEGV were included. Efficacy was defined as any normal IGF-I measurement during treatment. Safety data were reviewed. Predictors of response were determined by comparing controlled versus uncontrolled patients. Results 109 patients [61 women; median age at diagnosis 34 years; 95.3% macroadenomas] from 10 Brazilian centers were studied. Previous treatment included surgery (89%), radiotherapy (34%), somatostatin receptor ligands (99%), and cabergoline (67%). Before PEGV, median levels of GH, IGF-I and IGF-I % of upper limit of normal were 4.3 µg/L, 613 ng/mL, and 209%, respectively. Pre-diabetes/diabetes was present in 48.6% and tumor remnant in 71% of patients. Initial dose was 10 mg/day in all except 4 cases, maximum dose was 30 mg/day, and median exposure time was 30.5 months. PEGV was used as monotherapy in 11% of cases. Normal IGF-I levels was obtained in 74.1% of patients. Glycemic control improved in 56.6% of patients with pre-diabetes/diabetes. Exposure time, pre-treatment GH and IGF-I levels were predictors of response. Tumor enlargement occurred in 6.5% and elevation of liver enzymes in 9.2%. PEGV was discontinued in 6 patients and 3 deaths unrelated to the drug were reported. Conclusions In a real-life scenario, PEGV is a highly effective and safe treatment for acromegaly patients not controlled with other therapies.
Subject(s)
Humans , Male , Female , Child , Adolescent , Adult , Middle Aged , Aged , Aged, 80 and over , Young Adult , Acromegaly/drug therapy , Receptors, Somatostatin/therapeutic use , Human Growth Hormone/analogs & derivatives , Cabergoline/therapeutic use , Blood Glucose/analysis , Brazil , Insulin-Like Growth Factor I/analysis , Growth Hormone/blood , Adenoma/drug therapy , Predictive Value of Tests , Treatment Outcome , Drug Therapy, Combination , Cabergoline/administration & dosageABSTRACT
ABSTRACT Prolactinomas are the most common pituitary adenomas (approximately 40% of cases), and they represent an important cause of hypogonadism and infertility in both sexes. The magnitude of prolactin (PRL) elevation can be useful in determining the etiology of hyperprolactinemia. Indeed, PRL levels > 250 ng/mL are highly suggestive of the presence of a prolactinoma. In contrast, most patients with stalk dysfunction, drug-induced hyperprolactinemia or systemic diseases present with PRL levels < 100 ng/mL. However, exceptions to these rules are not rare. On the other hand, among patients with macroprolactinomas (MACs), artificially low PRL levels may result from the so-called "hook effect". Patients harboring cystic MACs may also present with a mild PRL elevation. The screening for macroprolactin is mostly indicated for asymptomatic patients and those with apparent idiopathic hyperprolactinemia. Dopamine agonists (DAs) are the treatment of choice for prolactinomas, particularly cabergoline, which is more effective and better tolerated than bromocriptine. After 2 years of successful treatment, DA withdrawal should be considered in all cases of microprolactinomas and in selected cases of MACs. In this publication, the goal of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism (SBEM) is to provide a review of the diagnosis and treatment of hyperprolactinemia and prolactinomas, emphasizing controversial issues regarding these topics. This review is based on data published in the literature and the authors' experience.
Subject(s)
Humans , Male , Female , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/therapy , Hyperprolactinemia/diagnosis , Hyperprolactinemia/therapy , Prolactinoma/diagnosis , Practice Guidelines as Topic , Prolactin/blood , Brazil , Prolactinoma/therapy , Bromocriptine/therapeutic use , Dopamine Agonists/therapeutic use , Ergolines/therapeutic use , Cabergoline , Antineoplastic Agents/therapeutic useABSTRACT
ABSTRACT The treatment objectives for a patient with Cushing's disease (CD) are remission of hypercortisolism, adequate management of co-morbidities, restoration of the hypothalamic-pituitary-adrenal axis, preservation of fertility and pituitary function, and improvement of visual defects in cases of macroadenomas with suprasellar extension. Transsphenoidal pituitary surgery is the main treatment option for the majority of cases, even in macroadenomas with low probability of remission. In cases of surgical failure, another subsequent pituitary surgery might be indicated in cases with persistent tumor imaging at post surgical magnetic resonance imaging (MRI) and/or pathology analysis of adrenocorticotropic hormone-positive (ACTH+) positive pituitary adenoma in the first procedure. Medical treatment, radiotherapy and adrenalectomy are the other options when transsphenoidal pituitary surgery fails. There are several options of medical treatment, although cabergoline and ketoconazole are the most commonly used alone or in combination. Novel treatments are also addressed in this review. Different therapeutic approaches are frequently needed on an individual basis, both before and, particularly, after surgery, and they should be individualized. The objective of the present review is to provide the necessary information to achieve a more effective treatment for CD. It is recommended that patients with CD be followed at tertiary care centers with experience in treating this condition.
Subject(s)
Humans , Societies, Medical , Pituitary ACTH Hypersecretion/therapy , Algorithms , BrazilABSTRACT
RESUMO Objetivo: mensurar a eficácia da perda de peso, analisar a evolução de comorbidades, investigar a qualidade de vida e avaliar o protocolo BAROS (Bariatric Analysis and Reporting Outcome System) no pós-operatório de pacientes submetidos à cirurgia bariátrica. Métodos: estudo transversal e quantitativo, com força de verdade de 95% (P=0,05), de 103 pacientes submetidos à Gastrectomia Vertical SLEEVE (40) e à Derivação Gástrica em Y de Roux (63), a partir de quatro meses de pós-operatório. A pesquisa foi realizada no Ambulatório de Cirurgia Geral do Hospital das Clínicas da Universidade Federal de Pernambuco, tendo sido utilizado o protocolo BAROS. Resultados: a maioria dos pacientes era do sexo feminino (89,3%). A média de idade foi de 44,23 anos. A média de perda percentual do excesso de peso foi de 69,35%. A média de tempo de seguimento pós-cirúrgico foi de 41,87 meses (±37,35). As comorbidades com maior percentagem de resolução foram: apneia do sono (90,2%), diabetes (80,7%) e hipertensão (70,8%). As complicações mais frequentes foram queda de cabelo (79,6%), deficiência nutricional (37,9%) e anemia (35%). O protocolo BAROS demonstrou que a qualidade de vida foi avaliada de forma positiva em 93,2% dos casos. O questionário Moorehead-Ardelt demonstrou que a qualidade de vida "melhorou" ou "melhorou muito" para 94,1% dos pacientes. Conclusão: a cirurgia bariátrica demonstrou ser um procedimento eficaz no tratamento da obesidade mórbida e no controle das comorbidades. A análise da qualidade de vida foi avaliada de forma positiva através do protocolo BAROS.
ABSTRACT Objective: to assess the efficacy of weight loss, the evolution of comorbidities, the quality of life and the BAROS protocol (Bariatric Analysis and Reporting Outcome System) in the postoperative period of patients undergoing bariatric surgery. Methods: we conducted a cross-sectional, quantitative study with 95% true strength (P=0.05), with 103 patients submitted to SLEEVE Vertical Gastrectomy (40) and Roux-en-Y Gastric Bypass (63), from four months after surgery. We carried out the research at the Ambulatory of General Surgery of the Clinics Hospital of the Federal University of Pernambuco, using the BAROS protocol. Results: the majority of the patients were female (89.3%). The mean age was 44.23 years. The mean percentage loss of excess weight was 69.35%. The mean postoperative follow-up time was 41.87 months (±37.35). The comorbidities with the highest percentage of resolution were sleep apnea (90.2%), diabetes (80.7%) and hypertension (70.8%). The most frequent complications were hair loss (79.6%), nutritional deficiency (37.9%) and anemia (35%). The BAROS protocol demonstrated that patients positively evaluated quality of life in 93.2% of the cases. The Moorehead-Ardelt questionnaire showed that quality of life "improved" or "improved greatly" for 94.1% of patients. Conclusion: bariatric surgery has been shown to be an effective procedure in the treatment of morbid obesity and in the control of comorbidities. Quality of life analysis was evaluated positively through the BAROS protocol.
Subject(s)
Humans , Male , Female , Adult , Young Adult , Quality of Life/psychology , Gastric Bypass/methods , Weight Loss/physiology , Bariatric Surgery/methods , Gastrectomy/methods , Postoperative Complications , Self Concept , Time Factors , Obesity, Morbid/surgery , Obesity, Morbid/physiopathology , Obesity, Morbid/epidemiology , Brazil/epidemiology , Gastric Bypass/psychology , Body Mass Index , Comorbidity , Cross-Sectional Studies , Surveys and Questionnaires , Treatment Outcome , Bariatric Surgery/psychology , Gastrectomy/psychology , Middle AgedABSTRACT
ABSTRACT Objective: to investigate changes in body image perception in patients undergoing bariatric surgery, evaluating the accuracy/inaccuracy in body size estimation and satisfaction/dissatisfaction with own body after surgery. Methods: we performed a survey at the General Surgery outpatient clinic of the Clinics Hospital of the Federal University of Pernambuco. Thirty-six patients aged 18 years and older undergoing bariatric surgery participated. We carried out cross-sectional and quantitative studies using the Silhouetted Figures Scale. Results: in the descriptive analysis of the distortion and dissatisfaction score of the patients with the body image, the mean distortion was positive (6.43kg/m²), indicating that most people see themselves greater than they really are. On the other hand, in the dissatisfaction, we found a negative mean (-6.91kg/m²), indicating that the majority of the patients evaluated had a "BMI" lower than the current one (that is, a smaller silhouette). Regarding satisfaction with silhouette size, only 11.8% of women liked the post-surgical result, while among men there was 50% satisfaction. Conclusion: Although bariatric surgery significantly reduced BMI, the patients presented, for the most part, dissatisfaction with body weight, perceiving it greater than it actually was, thus characterizing a perceptual inaccuracy.
RESUMO Objetivo: investigar as mudanças sofridas na percepção da imagem corporal em pacientes submetidos à cirurgia bariátrica, avaliando a acurácia/inacurácia na estimativa do tamanho corporal e a satisfação/insatisfação com os corpos após a cirurgia. Métodos: pesquisa foi realizada no ambulatório de Cirurgia Geral do Hospital das Clínicas da Universidade Federal de Pernambuco. Participaram 36 pacientes com idade a partir de 18 anos submetidos à cirurgia bariátrica. Foram realizados estudos transversal e quantitativo com a utilização da Escala de Figuras de Silhuetas. Resultados: na análise descritiva do escore de distorção e insatisfação dos pacientes com a imagem corporal, percebeu-se que a média da distorção foi positiva (média= 6,43kg/m²), indicando que a maioria das pessoas se vê maior do que realmente é. Em contrapartida, na insatisfação foi encontrada uma média negativa (média= -6,91kg/m²), indicando que a maioria dos pacientes avaliados tem como "meta" um IMC menor do que aquele apontado como atual (ou seja, gostaria de ter uma silhueta menor). Quanto à satisfação com o tamanho da silhueta, apenas 11,8% das mulheres gostaram do resultado pós-cirúrgico, enquanto que entre os homens houve 50% de satisfação. Conclusão: embora a cirurgia bariátrica tenha diminuído significativamente o IMC, os pacientes apresentaram, em sua maioria, insatisfação com o peso corporal, percebendo-o maior do que realmente era, caracterizando-se, assim, uma inacurácia perceptiva.
Subject(s)
Humans , Male , Female , Adult , Body Image , Patient Satisfaction , Bariatric Surgery/psychology , Cross-Sectional Studies , Self Report , Middle AgedABSTRACT
Hyperprolactinemia is a frequent condition in clinical practice, responsible for 20-25% of secondary amenorrhea cases. We performed an electronic survey among members of the Brazilian Society of Metabolism and Endocrinology (SBEM) and the Brazilian Federation of Association of Gynecology and Obstetrics (FEBRASGO) to assess diagnostic and therapeutic preferences for management of hyperprolactinemia. Electronic addresses of SBEM and FEBRASGO members were obtained from the directories of these societies, and these members were invited, through electronic messages (e-mail), to answer an online questionnaire that included 10 questions about the treatment of micro and macropro-lactinomas, maximum dose of dopamine agonist, how to exclude primary hypothyroidism and macroprolactinemia, hyperprolactinemia and pregnancy. We received responses to the questionnaire by e-mail from 521 SBEM members and 233 FEBRASGO members. The results of this survey demonstrate that there are many area of agreement between SBEM and FEBRASGO members and most of their responses follow the latest Endocrine Society Guideline. Relative to a survey performed several years ago, our findings show that SBEM members have incorporated some of latest recommendations in this field. The principal issues of concern for both groups are duration of dopamine agonist treatment for patients with microprolactinoma and dopamine agonist withdrawal during pregnancy.
La hiperprolactinemia es una alteración frecuente, siendo responsable del 20 al 25% de los casos de amenorrea secundaria. Se realizó una investigación electrónica entre los miembros de la Sociedad Brasileña de Endocrinología y Metabología (SBEM) y de la Federación Brasileña de Ginecología y Obstetricia (FEBRASGO) para evaluar sus preferencias en el diagnóstico y el tratamiento de la hiperprolactinemia. Las direcciones electrónicas de miembros SBEM y de FEBRASGO se obtuvieron a partir de los directorios de esas sociedades. Se invitó a estos miembros a responder un cuestionario que incluía 10 cuestiones sobre el tratamiento de los micro y macroprolactinomas, dosis máxima del agonista dopaminérgico, hiperprolactinemia e hipotiroidismo primario, macroprolactinemia, prolactinoma y embarazo. Hemos recibido respuestas de 521 miembros de la SBEM y de 233 miembros FEBRASGO. Los resultados demuestran que hay bastantes áreas de concordancia entre los miembros de la SBEM y de la FEBRASGO y que la mayoría de las respuestas están de acuerdo con el último consenso de la Endocrine Society. En cuanto a una encuesta similar realizada hace años, nuestros resultados muestran que los socios de SBEM incorporaron algunas de las últimas recomendaciones propuestas en esa área. Los principales aspectos de interés en ambos grupos son la duración del tratamiento con el agonista dopaminérgico y la retirada del mismo durante el embarazo.
Subject(s)
Humans , Female , Hyperprolactinemia/diagnosis , Hyperprolactinemia/therapy , Brazil , Prolactinoma/therapy , Dopamine Agonists/administration & dosage , Research ReportABSTRACT
ABSTRACT BACKGROUND Bariatric surgery is the most effective treatment for severe obesity, but the surgery increases the risk of developing nutritional deficiencies, such as vitamin A deficiency. In human metabolism, vitamin A plays a role in vision. OBJECTIVE To evaluate serum vitamin A, visual function and ocular surface of patients undergoing bariatric surgery. METHODS A cross-sectional and analytical study was conduced with 28 patients undergoing bariatric surgery for at least 6 months. Ophthalmologic evaluation was done through color vision test, contrast sensitivity test, ocular surface tests and confocal microscopy, as well as vitamin A serum measurement. RESULTS Vertical sleeve gastrectomy was performed in seven (25.0%) patients and Roux -en-Y gastric by-pass in 21 (75.0%). Mean serum vitamin A level was 1.7±0.5 µmoL/L. Most patients (60.7%) had symptoms of dry eye. Five (17.9%) patients had contrast sensitivity impairment and 18 (64.3%) color vision changes. In the group of patients undergoing Roux -en-Y gastric by-pass , mean vitamin A levels were 1.8±0.6 µmoL/L, whereas they were 1.7±0.5 µmoL/L in patients submitted to the restrictive technique vertical sleeve gastrectomy . The analysis of the influence of serum levels of vitamin A in the visual function and ocular surface was performed by Pearson correlation test and there was no significant correlation between any of the variables and vitamin A. CONCLUSION There was no influence of the bariatric surgery technique used on serum vitamin A levels, on the visual function or on the ocular surface. Moreover, there was no correlation between serum levels of vitamin A and the visual function or the ocular surface changes.
RESUMO CONTEXTO A cirurgia bariátrica é o tratamento mais efetivo para obesidade grave, entretanto aumenta o risco de desenvolvimento de deficiência de nutrientes, como vitamina A. No metabolismo humano, a vitamina A exerce função importante na visão. OBJETIVO Avaliar níveis séricos de vitamina A, função visual e superfície ocular de pacientes submetidos à cirurgia bariátrica. MÉTODOS Estudo transversal e analítico. População de 28 pacientes submetidos à cirurgia bariátrica há pelo menos 6 meses. Foi feita avaliação oftalmológica por meio de teste de visão de cores, teste de sensibilidade ao contraste, acuidade visual com correção, testes de superfície ocular e microscopia confocal, além da dosagem de vitamina A sérica. RESULTADOS Sete (25,0%) pacientes foram submetidos à gastrectomia vertical e 21 (75,0%), à derivação gástrica em Y de Roux. A média do valor sérico de vitamina A foi de 1,7±0,5 µmoL/L. A maioria dos pacientes (60,7%) apresentavam sintomas de olho seco. Cinco (17,9%) pacientes apresentaram alteração da sensibilidade ao contraste e 18 (64,3%) alteração da visão de cores. Quando considerados apenas os pacientes submetidos à derivação gástrica em Y de Roux, a média de vitamina A foi de 1,8±0,6 µmoL/L, enquanto os submetidos à técnica gastrectomia vertical tiveram média de 1,7±0,5 µmoL/L. A análise da influência dos níveis séricos de vitamina A na função visual e na superfície ocular foi realizada pelo teste de correlação de Pearson e não houve correlação significativa. CONCLUSÃO Não houve influência do tipo de técnica de cirurgia bariátrica utilizada nos níveis séricos de vitamina A, na função visual, nem na superfície ocular. Da mesma forma, não houve correlação dos níveis séricos de vitamina A com a função visual nem com as alterações de superfície ocular.
Subject(s)
Humans , Male , Female , Adult , Vitamin A/blood , Endothelium, Corneal , Visual Acuity/physiology , Bariatric Surgery/adverse effects , Vision Disorders/etiology , Vision Disorders/physiopathology , Obesity, Morbid/surgery , Cross-Sectional Studies , Treatment Outcome , Microscopy, Confocal , Middle AgedABSTRACT
ABSTRACT Clinically nonfunctioning pituitary adenomas (NFPA) are the most common pituitary tumors after prolactinomas. The absence of clinical symptoms of hormonal hypersecretion can contribute to the late diagnosis of the disease. Thus, the majority of patients seek medical attention for signs and symptoms resulting from mass effect, such as neuro-ophthalmologic symptoms and hypopituitarism. Other presentations include pituitary apoplexy or an incidental finding on imaging studies. Mass effect and hypopituitarism impose high morbidity and mortality. However, early diagnosis and effective treatment minimizes morbidity and mortality. In this publication, the goal of the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism is to provide a review of the diagnosis and treatment of patients with NFPA, emphasizing that the treatment should be performed in reference centers. This review is based on data published in the literature and the authors’ experience. Arch Endocrinol Metab. 2016;60(4):374-90.
Subject(s)
Humans , Male , Female , Pituitary Neoplasms/diagnosis , Pituitary Neoplasms/therapy , Neuroendocrinology , Adenoma/diagnosis , Societies, Medical , Brazil , Magnetic Resonance Imaging , Adenoma/therapy , Risk Factors , Early Diagnosis , Antineoplastic Agents/therapeutic useABSTRACT
ABSTRACT Although it is a rare condition, the accurate diagnosis and treatment of Cushing’s disease is important due to its higher morbidity and mortality compared to the general population, which is attributed to cardiovascular diseases, diabetes mellitus and infections. Screening for hypercortisolism is recommended for patients who present multiple and progressive clinical signs and symptoms, especially those who are considered to be more specific to Cushing’s syndrome, abnormal findings relative to age (e.g., spinal osteoporosis and high blood pressure in young patients), weight gain associated with reduced growth rate in the pediatric population and for those with adrenal incidentalomas. Routine screening is not recommended for other groups of patients, such as those with obesity or diabetes mellitus. Magnetic resonance imaging (MRI) of the pituitary, the corticotropin-releasing hormone (CRH) test and the high-dose dexamethasone suppression test are the main tests for the differential diagnosis of ACTH-dependent Cushing’s syndrome. Bilateral and simultaneous petrosal sinus sampling is the gold standard method and is performed when the triad of initial tests is inconclusive, doubtful or conflicting. The aim of this article is to provide information on the early detection and establishment of a proper diagnosis of Cushing’s disease, recommending follow-up of these patients at experienced referral centers. Arch Endocrinol Metab. 2016;60(3):267-86.
Subject(s)
Humans , Adenoma/diagnosis , Cushing Syndrome/diagnosis , Consensus , ACTH-Secreting Pituitary Adenoma/diagnosis , Brazil , Dexamethasone , Hydrocortisone/blood , Magnetic Resonance Imaging , Adenoma/complications , Chromatography, High Pressure Liquid , Cushing Syndrome/etiology , Diagnosis, Differential , ACTH-Secreting Pituitary Adenoma/complications , GlucocorticoidsABSTRACT
Background -Overweight and obesity are associated with metabolic syndrome and abdominal obesity, thereby increasing the risk of type 2 diabetes mellitus and cardiovascular diseases. In Brazil, there are still no precise data on the prevalence of these disorders, especially among individuals who carry out some kind of physical activity in public spaces and there are no education and prevention programs for obesity.Aim:To investigate the prevalence of metabolic syndrome and obesity among park users.Methods:A prospective, cross-sectional, descriptive study was conducted with 619 individuals assessed and stratified by profile according to a specific protocol. The group was characterized as follows: female (50.1%) and mean age =50.6±14.8, with predominance of individuals aged between 50 and 59 years (26.8%) and with higher education (68%) and a household income of between 4 and 10 minimum wages (29.2%).Results:Regular physical exercise was reported by 78% of the individuals and it was found that 70.7% were nevertheless of above normal weight: 45% overweight and 25.7% obese, of whom 20.7% had obesity grade I, 3.9% grade II and 1.1% grade III. The prevalence of metabolic syndrome was 4.3%, mostly in men (6.3%). Arterial hypertension and type 2 diabetes mellitus were detected in 17.8% and 5.5%, respectively. In view of the influence of obesity on the occurrence of type 2 diabetes mellitus and metabolic syndrome, it was found that this association was not significant for the two conditions (p=0.014 and 0.017, respectively).Conclusion: The findings demonstrate a high prevalence of overweight and obesity in the studied population, and metabolic syndrome in 4.3%, despite the fact that 70% reported engaging in regular physical activity.
Racional:Sobrepesoe obesidade estão associados à síndrome metabólica e obesidade abdominal, aumentando o risco de diabete melito tipo 2 e doenças cardiovasculares. No Brasil, ainda não há dados precisos sobre a prevalência destas alterações, principalmente entre pessoas que estão realizando algum tipo de atividade física em ambientes públicos; também não há programas de educação e prevenção da obesidade.Objetivo:Investigar a prevalência da obesidade e síndrome metabólica em frequentadores de um parque em Recife.Métodos:Realizou-se um estudo prospectivo, transversal e descritivo, onde 619 indivíduos foram avaliados e estratificados por perfil definido em protocolo específico, apresentando as seguintes características: sexo feminino (50,1%) e média de idade = 50,6 ± 14,8, havendo predomínio entre 50 e 59 anos (26,8% dos casos) e de indivíduos com ensino superior (68%) e renda familiar entre 4 e 10 salários mínimos (29,2%).Resultados:Prática regular de exercícios físicos foi relatada por 78% das pessoas e foi constatado ainda que 70,7% apresentavam excesso de peso: 45% com sobrepeso e 25,7% obesidade, dos quais 20,7% com obesidade grau I, 3,9% com grau II e 1,1% com grau III. A prevalência de síndrome metabólica foi de 4,3%, com predomínio nos homens (6,3%). Hipertensão arterial e diabetes mellitus tipo 2 foram detectados em 17,8% e 5,5%, respectivamente. Devido a influência da obesidade na ocorrência de diabetes mellitus 2 e síndrome metabólica, foi constatado que esta associação não é significativa para as duas condições (p=0,014 e 0,017, respectivamente).Conclusão: Os achados demonstram elevada prevalência de sobrepeso e obesidade da população avaliada, e síndrome metabólica em 4,3%, apesar do relato de que 70% dos transeuntes realizavam atividade física regular.
ABSTRACT
The definition of the etiology of hyperprolactinemia often represents a great challenge and an accurate diagnosis is paramount before treatment. Although prolactin levels > 200-250 ng/mL are highly suggestive of prolactinomas, they can occasionally be found in other conditions. Moreover, as much as 25% of patients with microprolactinomas may present prolactin levels < 100 ng/mL, which are found in most patients with pseudoprolactinomas, drug-induced hyperprolactinemia, or systemic diseases. On the other hand, some conditions may lead to falsely low PRL levels, particularly the so-called hook effect, that is an assay artifact caused by an extremely high level of PRL, and can be confirmed by repeating assay after a 1:100 serum sample dilution. The hook effect must be considered in all patients with large pituitary adenomas and PRL levels within the normal range or only modestly elevated (e.g., < 200 ng/mL). An overlooked hook effect may lead to incorrect diagnosis and unnecessary surgical intervention in patients with prolactinomas. Another important challenge is macroprolactinemia, a common finding that needs to be identified, as it usually requires no treatment. Although most macroprolactinemic patients are asymptomatic, many of them may present galactorrhea or menstrual disorders, as well as neuroradiological abnormalities, due to the concomitance of other diseases. Finally, physicians should be aware that pituitary incidentalomas are found in at least 10% of adult population. Arq Bras Endocrinol Metab. 2014;58(1):9-22.
A definição da etiologia da hiperprolactinemia muitas vezes representa um grande desafio e um diagnóstico preciso é fundamental antes do tratamento. Embora níveis de prolactina > 200-250 ng/mL sejam altamente sugestivos de prolactinomas, ocasionalmente podem ser encontrados em outras condições. Além disso, até 25% dos pacientes com microprolactinomas podem apresentar-se com níveis de prolactina < 100 ng/mL, os quais são evidenciados na maioria dos pacientes com pseudoprolactinomas, hiperprolactinemia induzida por drogas ou doenças sistêmicas. Por outro lado, deve-se atentar às condições que podem levar a valores de prolactina falsamente baixos, particularmente o chamado efeito gancho. Este último é um artefato causado por um nível extremamente elevado de PRL e que pode ser confirmado pela repetição do exame após diluição do soro a 1:100. O efeito gancho deve ser considerado em todo paciente com grandes adenomas hipofisários e níveis de prolactina dentro da faixa normal ou apenas moderadamente elevados (p. ex., < 200 ng/mL). Um efeito gancho não detectado pode levar a diagnóstico incorreto e intervenção cirúrgica desnecessária em pacientes com prolactinomas. Outro desafio importante é a macroprolactinemia, um achado comum que precisa ser identificado visto que geralmente não requer tratamento. Ainda que a maioria dos pacientes seja assintomática devido à concomitância de outras doenças, muitos podem apresentar galactorreia ou distúrbios menstruais, bem como anormalidades neurorradiológicas. Finalmente, os médicos devem estar cientes de que incidentalomas hipofisários são encontrados em pelo menos 10% da população adulta. Arq Bras Endocrinol Metab. 2014;58(1):9-22.
Subject(s)
Female , Humans , Male , Hyperprolactinemia/diagnosis , Hyperprolactinemia/etiology , Prolactin/blood , Prolactinoma/complications , Chemical Precipitation , Chromatography, Gel , Galactorrhea/etiology , Magnetic Resonance Imaging , Medical History Taking , Physical Examination , Prolactin/classificationABSTRACT
RACIONAL: Alterações metabólicas têm elevada correlação com formas graves da doença hepática gordurosa não-alcoólica. Todavia, ainda não há método não-invasivo que promova sua adequada estratificação sendo que a biópsia permanece como meio diagnóstico ideal. OBJETIVO: Avaliar a prevalência dessa doença em obesos no pré-operatório de bypass gástrico em Y-de-Roux e correlacionar fatores metabólicos com a histopatologia hepática. MÉTODOS: Do total de 47 pacientes, foram incluídos 35 em pré-operatório e excluídos 12 devido à doenças hepáticas e ingestão alcoólica >80 g/semana. Foi realizada avaliação clínico-laboratorial antes da operação e biópsia hepática transoperatória. A intensidade da esteatohepatite foi classificada nos graus: I (leve a moderada), II (difusa e inflamatória), III (fibrose periportal) e IV (cirrose). Foram comparadas as seguintes variáveis: tempo de obesidade, índice de massa corpórea, relação cintura-quadril, diabete melito tipo 2, hipertensão arterial e dislipidemia. RESULTADOS: Trinta e cinco pacientes (68,6% mulheres, média de idade de 37 anos) foram avaliados. O índice de massa corpórea médio pré-operatório foi de 53,04 kg/m2. Esteatohepatite não-alcoólica foi encontrada em 31 pacientes (88,6%), sendo grau I 32,2% (n=10), grau II 45,2% (n=14), e grau III 25,6% (n=7). A relação cintura-quadril mostrou associação com esteatose hepática; hipertrigliceridemia foi o marcador que melhor se correlacionou com maior grau; não houve correlação entre aminotransferase e a intensidade da doença; houve correlação da intensidade com fatores relacionados à resistência insulínica. CONCLUSÃO: Esteatohepatite não-alcoólica tem elevada prevalência em obesos graves, porém não foi observada correlação positiva entre aminotransferases e o grau de obesidade com histopatologia hepática. Hipertrigliceridemia e relação cintura-quadril correlacionaram-se positivamente com a intensidade de doença.
BACKGROUND: Metabolic disorders have high correlation with severe forms of nonalcoholic fatty liver disease. However, there is no non-invasive method that promotes its proper stratification and biopsy remains the ideal diagnostic tool. AIM: To evaluate the prevalence of this disease in obese in preoperative period of Roux-en-Y gastric bypass and metabolic factors correlated with liver histopathology. METHODS: From a total of 47 patients, 35 were enrolled in the inclusion criteria and 12 excluded due to liver disease and alcohol intake >80 g/week. Were performed clinical and laboratory evaluation before the surgery and intraoperative liver biopsy . The intensity was ranked in grade of steatohepatitis: I (mild to moderate) and II (diffuse inflammation), III ( periportal fibrosis) and IV (cirrhosis). Were compared the following variables: duration of obesity, body mass index, waist-hip ratio, type 2 diabetes mellitus, hypertension and dyslipidemia. RESULTS: Thirty -five patients (68.6 % women , mean age 37 years) were evaluated. The mean body mass index preoperatively was 53.04 kg/m². Nonalcoholic steatohepatitis was found in 31 patients (88.6 %) and 32.2% were in grade I (n=10), grade II 45.2% (n=14), and 25.6% grade III (n=7). The waist-hip ratio was associated with hepatic steatosis; hypertriglyceridemia was the marker that had best correlation with higher grade; there was no correlation between aminotransferase and intensity of the disease; there was correlation of intensity with factors related to insulin resistance. CONCLUSION: Nonalcoholic steatohepatitis is highly prevalent in morbidly obese patients, but there was no positive correlation between aminotransferases and degree of obesity and liver histopathology. Hypertriglyceridemia and waist-hip ratio were positively correlated with the intensity of disease.
Subject(s)
Adult , Female , Humans , Male , Fatty Liver/complications , Fatty Liver/epidemiology , Gastric Bypass , Obesity, Morbid/complications , Obesity, Morbid/surgery , Body Mass Index , Fatty Liver/metabolism , Fatty Liver/pathology , Obesity, Morbid/metabolism , Preoperative Period , Prevalence , Severity of Illness Index , Waist-Hip RatioABSTRACT
Acromegalia é uma doença endócrina rara. Poucos estudos avaliaram sua associação com deficiência auditiva (DA) e os resultados são conflitantes. OBJETIVOS: Avaliar a prevalência e características da DA em um grupo de pacientes com acromegalia em tratamento. Analisar a transmissão auditiva central e periférica. MATERIAL E MÉTODOS: Estudo transversal. Um grupo de 34 pacientes com acromegalia submeteu-se à avaliação metabólica, audiometria tonal e potenciais evocados auditivos de tronco encefálico (PEATE). Considerou-se DA quando a média dos tons puros foi > 25 DBNA para baixas frequências (250, 500, 1000 e 2000 Hz) ou altas frequências (3000, 4000, 6000 e 8000 Hz). Os pacientes foram divididos em grupo A (com DA) e B (sem DA). RESULTADOS: Doze pacientes (35,3%) mostraram DA sensorioneural (grupo A), sendo oito bilateral e quatro unilateral. Nenhum apresentou DA mista ou condutiva. A prevalência de diabetes/intolerância à glicose de jejum foi similar entre os grupos. As frequências de 3000, 4000, 6000 e 8000 Hz foram as mais afetadas e com padrão similar em ambos os lados. CONCLUSÃO: DA sensorioneural esteve presente em 35,3% dos casos. Não foram notadas diferenças clínicas ou metabólicas significativas entre os grupos, bem como na transmissão neural auditiva periférica e central.
Acromegaly is a rare endocrine disease. Few studies have evaluated its association with hearing loss (HL) and the results are conflicting. AIM: To evaluate the prevalence and features of HL in a group of patients being treated for acromegaly. To analyze peripheral and central auditory transmission. METHODS: Cross-sectional study. A group of 34 patients with acromegaly were submitted to metabolic evaluation, tonal audiometry and brainstem auditory evoked potentials. HL was considered when pure tone average was > 25 DBHL for low frequencies (250, 500, 1000 and 2000 Hz) or high frequencies (3000, 4000, 6000 and 8000 Hz). The patients were divided in group A (with HL) and B (without HL). RESULTS: Twelve patients (35.3%) had sensorineural HL (Group A), being 8 bilateral and 4 unilateral. No one had mixed or conductive HL. The prevalence of diabetes/impaired glucose tolerance was similar between the groups. The frequencies 3000, 4000, 6000 and 8000 Hz were the most affected and with a similar pattern in both ears. CONCLUSION: sensorineural HL was found in 38.9% of cases. Neither clinical nor metabolic differences were noted between the groups, as well as in regards to peripheral and central auditory transmission.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Acromegaly/complications , Hearing Loss, Sensorineural/etiology , Audiometry, Pure-Tone , Cohort Studies , Cross-Sectional Studies , Evoked Potentials, Auditory, Brain Stem , Hearing Loss, Sensorineural/diagnosisSubject(s)
Humans , Acromegaly/diagnosis , Acromegaly/therapy , Brazil , Human Growth Hormone , SyndromeABSTRACT
OBJECTIVE: To evaluate the effectiveness of adding vildagliptin to the treatment of patients with inadequately controlled type 2 diabetes mellitus (T2DM) treated with a combination of metformin and a sulphonylurea. SUBJECTS AND METHODS: 37 T2DM patients with HbA1c ranging from 7.7 percent to 12.4 percent (mean of 9.30 ± 1.38), despite the use of metformin in combination with a sulphonylurea, were additionally treated with vildagliptin (100 mg/day) for at least 6 months. RESULTS: During triple oral therapy (TOT) HbA1c levels < 7 percent were achieved in 11 patients (29.7 percent), whereas levels of fasting plasma glucose (FPG) < 120 mg/dL were observed in 12 patients (32.4 percent). Both findings were observed in 10 patients (27.0 percent). Compared to nonresponsive subjects, lower mean baseline HbA1c and FPG levels were seen in responsive patients, but the difference was only statistically significant for fasting plasma glucose (FPG). Moreover, there was considerable overlap between the two groups. CONLUSION: Our preliminary results suggest that TOT with metformin, a sulphonylurea and vildagliptin may be useful for some T2DM patients nonresponsive to combination therapy with metformin and sulphonylurea.
OBJETIVO: Avaliar a eficácia da adição de vildagliptina ao tratamento de pacientes com diabetes melito tipo 2 (DM2) inadequadamente controlados com a terapia de combinação com metformina e sulfonilureia. SUJEITOS E MÉTODOS: 37 pacientes com DM2 e HbA1c variando entre 7,7 por cento e 12,4 por cento (média, 9,30 ± 1,38), apesar do uso de metformina associada a uma sulfonilureia, foram adicionalmente tratados com vildagliptina (100 mg/dia) durante, pelo menos, 6 meses. RESULTADOS: Durante a terapia oral tripla TOT), níveis de HbA1c < 7 por cento foram alcançados em 11 pacientes (27,9 por cento), enquanto a glicemia de jejum (GJ) < 120 mg/dL foi observada em 12 pacientes (32,4.1 por cento). Ambos os resultados foram descritos em 10 pacientes (27,0 por cento). Em comparação com indivíduos não responsivos, os pacientes responsivos tinham níveis basais mais baixos de HbA1c e GJ, mas a diferença foi estatisticamente significativa somente para glicemia de jejum. Além disso, houve grande sobre-posição entre os dois grupos. CONSLUSÃO: Nossos resultados preliminares sugerem que a TOT com metformina, uma sulfonilureia e vildagliptina pode ser útil para alguns pacientes com DM2 não responsivos à combinação com metformina e uma sulfonilureia.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Adamantane/analogs & derivatives , /drug therapy , Hypoglycemic Agents/administration & dosage , Metformin/administration & dosage , Nitriles/therapeutic use , Pyrrolidines/therapeutic use , Sulfonylurea Compounds/therapeutic use , Administration, Oral , Analysis of Variance , Adamantane/therapeutic use , Blood Glucose/metabolism , /blood , Drug Therapy, Combination/methods , Fasting/blood , Glycated Hemoglobin/metabolism , Time Factors , Treatment Failure , Treatment OutcomeABSTRACT
A acromegalia é uma doença associada à elevada morbidade e à redução da expectativa de vida. Em virtude do seu caráter insidioso e do seu não reconhecimento, o diagnóstico é frequentemente realizado com atraso, o que, associado às complicações relacionadas ao excesso do GH/IGF-I, determina elevada morbimortalidade. No entanto, um diagnóstico precoce e um tratamento efetivo minimizam a morbidade e normalizam a taxa de mortalidade. Nesta publicação, o objetivo do Departamento de Neuroendocrinologia da Sociedade Brasileira de Endocrinologia e Metabologia é divulgar quando suspeitar clinicamente da acromegalia e como diagnosticá-la. Além disso, discute-se a maneira mais eficaz e segura de realizar o tratamento da acromegalia, enfatizando que este deve ser realizado em centros de referência. Assim, com base em dados publicados em periódicos de nível científico reconhecido e na experiência dos autores, são apresentadas as recomendações para o diagnóstico e tratamento da doença.
Acromegaly is a disease associated with increased morbidity and reduced life expectancy. Because of its insidious character and its non-recognition, the diagnosis is often made with delay, which, along with the complications related to GH/IGF-I excess, determines high morbidity and mortality. However, an early diagnosis and an effective treatment reduce the morbidity and normalize the mortality rate. In this publication, the goal of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism is to disclose which clinical set should arouse the suspicious of acromegaly and how to diagnose it. Furthermore, we discuss the most effective and safe approach to perform the treatment of acromegaly, emphasizing that it must be carried out in reference centers. Therefore, based on data published in journals with recognized scientific level and authors' experience, recommendations are presented for diagnosis and treatment of the disease.
Subject(s)
Humans , Acromegaly/diagnosis , Acromegaly/therapy , Brazil , Human Growth Hormone , SyndromeABSTRACT
OBJECTIVE: This study reports on the Brazilian Portuguese adaptation of the QoL-AGHDA (Quality of Life Assessment of Growth Hormone Deficiency in Adults) for use in adult growth hormone deficient (GHD) patients. MATERIALS AND METHODS: The translation process adopted the dual panel methodology. The questionnaire was tested through field-test interviews (16 GHD patients). In the final stage, data from 120 GHD patients (81 included in a test-retest analysis) were analyzed for internal consistency, test-retest reliability, convergent validity and validity among known groups. RESULTS: The translation panels were successful and the draft version was amended to improve the wording as a result of the field-test interviews. Cronbach's alpha was 0.90 and test-retest reliability 0.88. QoL-AGHDA scores had the expected pattern of association with NHP scale scores and QoL-AGHDA was able to differentiate significantly between patients based on patient-reported general health (p < 0.01) and QoL (p < 0.01). CONCLUSIONS: The adaptation of the QoL-AGHDA for a Brazilian population was successful and the adapted questionnaire was shown to be reliable and valid.
OBJETIVO: Este estudo relata o processo de adaptação da versão brasileira do questionário QoL-AGHDA (Quality of Life - Assessment of Growth Hormone Deficiency in Adults) para pacientes com deficiência do hormônio de crescimento (DGH). MATERIAIS E MÉTODOS: A tradução adotou a metodologia de duplo painel. O questionário foi testado por intermédio de entrevistas direcionadas com 16 pacientes com DGH. No estágio final, dados de 120 pacientes com DGH (81 com teste/reteste) foram analisados para consistência interna, confiabilidade teste/reteste, validade convergente e validade entre grupos conhecidos. RESULTADOS: Os grupos de tradução foram bem-sucedidos e a versão final foi adaptada seguindo sugestões obtidas das entrevistas com os 16 pacientes. O coeficiente alfa de Cronbach foi 0,90, confiabilidade teste/reteste 0,88, escores QoL-AGHDA se correlacionaram com o NHP (p < 0,01) e também com a saúde geral relatada pelos pacientes (p < 0,01). CONCLUSÕES: A adaptação do QoL-AGHDA para a população brasileira foi bem-sucedida, e a nova versão demonstrou ser válida e confiável.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Human Growth Hormone/deficiency , Quality of Life , Surveys and Questionnaires/standards , Translations , Brazil , Language , Reproducibility of Results , Statistics, NonparametricABSTRACT
OBJECTIVE: To evaluate the frequency of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (DM2) and to describe its risk factors. SUBJECTS AND METHODS: Blood samples of 78 patients were collected for assessment of glycemic and lipid profile, liver enzymes, TNF-α and HOMA-IR. The diagnosis of NAFLD was established by ultrasound. RESULTS: NAFLD was observed in 42 percent of patients who had greater BMI (p < 0.001), and frequency of hypertension (p < 0.001). Metabolic syndrome was more frequent in those with NAFLD (p = 0.019). The levels of aspartate, alanine aminotransferase, γ-glutamyl transpeptidase, uric acid, TNF-α, insulin and HOMA-IR were significantly higher in patients with NAFLD than those without NAFLD. CONCLUSION: Almost half of patients with DM2 were found to have NAFLD, and they have more elevated BMI, as well as higher levels of aminotransferases, γ-GT, uric acid, TNF-α, insulin and HOMA-IR than subjects without NAFLD.
OBJETIVO: Avaliar a frequência de doença hepática gordurosa não alcoólica (DHGNA) em pacientes com diabetes mellitus tipo 2 (DM2) e descrever seus fatores de risco. SUJEITOS E MÉTODOS: Amostras de sangue foram coletadas de 78 pacientes para avaliação dos perfis glicídico e lipídico, enzimas hepáticas, TNF-α e HOMA-IR. O diagnóstico de DHGNA foi estabelecido por ultrassonografia. RESULTADOS: NAFLD foi observada em 42 por cento dos pacientes que apresentaram maior IMC (p < 0,001). Hipertensão arterial sistêmica (p < 0,001) e síndrome metabólica foram mais frequentes naqueles com DHGNA (p = 0,019). Os níveis de aspartato aminotransferase, alanina aminotransferase, γ-glutamil transpeptidase, ácido úrico, TNF-α, insulina e HOMA-IR foram significativamente maiores nos pacientes com do que naqueles sem DHGNA. CONCLUSÃO: Quase metade dos pacientes com DM2 apresentaram DHGNA, os quais tiveram IMC mais elevado, bem como maiores níveis de aminotransferases, γ-GT, ácido úrico, TNF-α, insulina e HOMA-IR do que os indivíduos sem DHGNA.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , /complications , Fatty Liver/etiology , Body Mass Index , Biomarkers/blood , Chi-Square Distribution , /blood , Fatty Liver/diagnosis , Fatty Liver/epidemiology , Insulin Resistance/physiology , Risk Factors , Transaminases/blood , Tumor Necrosis Factor-alpha/bloodABSTRACT
OBJECTIVE: To compare the efficacy and tolerability of metformin, rosiglitazone and gliclazide MR as monotherapy and in combination in the treatment of type 2 diabetes. SUBJECTS AND METHODS: 250 patients treated with oral antidiabetic agents for at least 24 weeks in monotherapy or in combination therapy were included in this retrospective study. RESULTS: As monotherapy the reduction of fasting plasma glucose (FPG), postprandial glycemia (PPG) and HbA1c was similar with the three drugs after 24 weeks. Among patients on combination therapy, the reduction in HbA1c, FPG and PPG was significantly lower with rosiglitazone plus metformin, as compared to metformin plus gliclazide MR or gliclazide MR plus rosiglitazone. Patients treated with rosiglitazone achieved less favorable changes in lipid profile. CONCLUSION: In monotherapy all drugs were equally effective in improving glycemic control, whereas the combination of metformin plus gliclazide MR provided the best results concerning the improvement of both, glycemic control and lipid profile.
OBJETIVO: Comparar a eficácia e a tolerabilidade da metformina, rosiglitazona e gliclazida MR em monoterapia ou em combinação no tratamento do diabetes tipo 2. SUJEITOS E MÉTODOS: 250 pacientes tratados com antidiabéticos orais por pelo menos 24 semanas, em monoterapia ou em terapia combinada, foram incluídos neste estudo retrospectivo. RESULTADOS: Como monoterapia, a redução da glicemia de jejum (GJ), glicemia pós-prandial (GPP) e HbA1c foi similar com as três drogas, após 24 semanas. Entre os pacientes em terapia combinada, a redução da HbA1c, GJ e GPP foi significativamente menor com rosiglitazona e metformina, em comparação com metformina e gliclazida MR ou gliclazida MR mais rosiglitazona. Os pacientes tratados com rosiglitazona obtiveram mudanças menos favoráveis no perfil lipídico. CONCLUSÃO: Em monoterapia todos os medicamentos foram igualmente eficazes na melhora do controle glicêmico, enquanto a combinação de metformina e gliclazida MR proporcionou os melhores resultados relativos à melhoria de ambos, controle glicêmico e perfil lipídico.
Subject(s)
Adult , Aged , Female , Humans , Male , Middle Aged , /drug therapy , Gliclazide/adverse effects , Hypoglycemic Agents/adverse effects , Metformin/adverse effects , Thiazolidinediones/adverse effects , Analysis of Variance , /metabolism , Drug Therapy, Combination/adverse effects , Retrospective StudiesABSTRACT
Os prolactinomas são os tumores hipofisários mais comuns e têm como tratamento de escolha os agonistas dopaminérgicos, que propiciam normalização dos níveis de prolactina, redução tumoral e reversão da galactorreia e das manifestações do hipogonadismo na maioria dos casos. A cabergolina é preferível a bromocriptina por ser mais eficaz e mais bem tolerada. Todo macroprolactinoma, a princípio, deve ser tratado, e a terapia dos microprolactinomas pode ser reservada para casos de amenorreia, galactorreia incômoda, distúrbios sexuais ou infertilidade. Ainda existem controvérsias sobre a dose máxima desses medicamentos e sobre a duração ideal do tratamento. Sugerem os autores sua suspensão depois de 24 meses, caso tenha havido normalização dos níveis de prolactina, particularmente quando a ressonância magnética hipofisária não revele anormalidade.
Prolactinomas are the most common hipophisary tumors. Their treatment of choice are dopamine agonists that provide in most cases normalization of prolactin levels, tumor reduction and reversal of both galactorrhea and hypogonadism symptoms. Cabergoline is preferable to bromocriptine because it is more effective and better tolerated. While all macroprolactinomas, a priori, should be treated, the therapy of microprolactinomas can be reserved for cases of amenorrhea, bothersome galactorrhea, sexual disturbances or infertility. There is still controversy about the maximum dose of dopamine agonists and the ideal duration of treatment. The authors suggest treatment withdrawal after 24 months if there has been normalization of prolactin levels, particularly in patients with normal pituitary magnetic resonance findings.